New Therapeutic Options Could Shift Prostate Cancer Treatment
We will discuss the current prostate cancer treatments and key catalysts for older drugs facing loss of exclusivity. We will also discuss new therapies for prostate cancer, with protein degraders and T-cell engagers both aiming to hit the market in the near future.
Speakers
Max Nisen
Analyst
Bloomberg Intelligence
Max Nisen is a senior associate equity research analyst specializing in the pharmaceutical and biotechnology sector. Prior to joining Bloomberg Intelligence, Max was the founding health care columnist for Bloomberg Gadfly and later Bloomberg Opinion, where he wrote about the pharmaceutical industry, managed care, policy and public health. Before that, he covered business and financial news at Quartz and Business Insider. Max earned a bachelor’s degree in economics from Pomona College.